Simple Summary Microsatellite instability (MSI) is a hallmark of Lynch syndrome (LS)-related
tumors but is not specific, as most of MSI/mismatch repair-deficient (dMMR) tumors are …

Reflex mismatch repair immunohistochemistry (MMR IHC) testing for MLH1, PMS2, MSH2
and MSH6 is used to screen for Lynch syndrome. Recently MMR-deficiency (MMRd) has …

Context.—The US Food and Drug Administration (FDA) approved immune checkpoint
inhibitor therapy for patients with advanced solid tumors that have DNA mismatch repair …

Purpose There are no internationally agreed upon clinical guidelines as to which women
with gynecological cancer would benefit from Lynch syndrome screening or how best to …

Background Mismatch repair (MMR)-deficiency analysis is increasingly recommended for all
endometrial cancers, as it identifies Lynch syndrome patients, and is emerging as a …

Lynch syndrome (LS) is an autosomal dominant inherited disorder caused by germline
mutations in DNA mismatch repair (MMR) genes. Mutation carriers are at substantially …

DNA mismatch repair (MMR) proteins are essential for the recognition and correction of
sporadic genetic mutations that occur during DNA replication. Deficient MMR function …

BRAFV600E mutation in microsatellite-unstable (MSI) colorectal carcinomas (CRCs)
virtually excludes Lynch syndrome (LS). In microsatellite-stable (MSS) CRCs it predicts poor …

Universal screening for Lynch syndrome in colorectal cancer is recommended, and
immunohistochemistry for the mismatch repair proteins is commonly used. To reduce cost …

Background Lynch syndrome (LS) is a hereditary condition that increases the risk for
endometrial and other cancers. The identification of endometrial cancer (EC) patients with …